I am delighted to share some exciting news released today about the acquisition of ADAMAS Consulting Group Limited by Ergomed plc which will allow us to significantly expand our services. It is our belief that this acquisition will benefit and complement both Ergomed and ADAMAS in many ways. This provides both organizations with increased global coverage as well as aligning with Ergomed’s strategy to broaden its service offering to clients whilst ensuring quality and compliance remain central to its operational growth strategy.
Ergomed is a highly regarded business that shares our commitment to delivering regulatory compliance as well as the highest quality services to the global healthcare industry. Joining the Ergomed Group provides us with an even stronger platform and increased investment from which to further develop and scale up our offering and to continue to deliver gold standard quality assurance services.
ADAMAS will continue to operate as an independent consulting business and the existing senior executive team will continue in their current positions in the business, led by myself in my new role as President, ADAMAS Consulting.
The acquisition of ADAMAS by Ergomed Plc was finalized and announced on 9th February 2022. This is an excellent step forward for both ADAMAS and Ergomed. ADAMAS will join Ergomed and, it’s subsidiary, PrimeVigilance, Inc. to become a major contributor to the growth and development of our organization as a global leader in our sector.
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, pre- and post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, services business, includes a full range of high-quality contract research and clinical trial management (CRO) services together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand.
Should you have any questions regarding this announcement, please do not hesitate to ask. We look forward to further discussions.
Best regards,
